Please assess the completion status of the following clinical trial:

Trial Title: Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 Diabetes Mellitus on oral mono-therapy or diet only treatment~* Stable documented ischemic Heart disease (\>30 days post AMI, CABG or PCI)~* Sub-optimal Hb A1c as defined ≥6.5%~* Age \> 21~* Life expectancy \>1 year~Exclusion Criteria:~* Significant renal impairment (creatinine ≥1.4 mg\\dL females or ≥1.5 mg\\dL males)~* Planned coronary intervention or planed surgical intervention (PCI or CABG)~* Planned surgical intervention~* Recent (\<30 day) acute coronary syndrome (ACS)~* Hypersensitivity to either of the study drug components~* History of lactic acidosis~* Type I diabetes~* Current Hb A1c \>9%~* Current Insulin treatment~* Active treatment with GLP-1 or DPP4i medication~* Hepatic impairment or ALT\\AST elevations beyond X2 upper normal limit or known hepatic failure~* Inability to comply with study protocol~* Active malignancy other than basal cell carcinoma (BCC)~* Clinically advanced congestive heart failure - NYHA III-IV~* Severe left ventricular dysfunction (LVEF\<30%) with NYHA II or any NYHA class with documented recent heart failure decompensation (\<3 months)~* Severe stable cardiac angina CCS III - IV or Unstable angina~* Chronic inflammation (i.e. IBD, Lupus, inflammatory arthritis, rheumatoid arthritis) or chronic infection (i.e. chronic diabetic foot infection)~* Pregnancy, lactation or child-bearing potential

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vildagliptin+metformin (Type: EXPERIMENTAL): Oral Vildagliptin+metformin combination
- Metformin only (Type: ACTIVE_COMPARATOR): Oral metformin only

Based on this trial design, predict the completion outcome and termination type (if applicable).